Overview

Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the combination of Taxotere and exisulind is an effective and safe treatment for patients with advanced NSCLC who have failed a prior platinum-containing regimen.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
OSI Pharmaceuticals
Treatments:
Docetaxel
Sulindac
Sulindac sulfone